A

Business Profile & Competitive Position

Agilent Technologies, Inc. operates in the Healthcare sector under the Medical – Diagnostics & Research industry. The company provides application-focused solutions for life sciences, diagnostics and applied markets, selling instruments, software, services and consumables that cover the entire laboratory workflow. Following a November 2024 reorganization, Agilent reports through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. Distribution is primarily direct, supplemented by distributors, resellers, manufacturers’ representatives and e-commerce.

Relative to many hardware-heavy industrials, Agilent’s competitive economics look sturdy. Net margin stands at 19.6% and return on equity is 20.8%. A near-20% net margin suggests real pricing power and strong attach rates for services and consumables, while an ROE above 20% indicates the company is generating meaningful equity returns rather than simply operating at scale. Those figures also fit the profile of a diagnostics-and-research supplier whose revenue is partly recurring: installed instruments tend to drive ongoing demand for consumables, software and service contracts. The company employed approximately 18,100 people worldwide as of October 31, 2025, with the largest concentration in Agilent CrossLab at roughly 7,400 employees, followed by 6,300 in Life Sciences and Diagnostics Markets and 2,500 in Applied Markets. Its primary R&D and manufacturing footprint spans California, Colorado, Delaware, Massachusetts, Texas and Vermont in the U.S., plus Australia, Canada, China, Denmark, Germany, Italy, Japan, Malaysia, Singapore and the United Kingdom.

Financial Posture

Agilent carries a market capitalization of $43.4 billion and trades at a trailing P/E of 30.8 as of the current snapshot. That valuation sits at a clear premium to the broader U.S. equity market, which is consistent with a profitable, globally diversified healthcare tools business. The same profitability metrics that support the moat reading—19.6% net margin and 20.8% ROE—also help justify a higher multiple, though the P/E leaves limited room for disappointment. Beta is 1.23, meaning Agilent has historically moved about 23% more than the overall market, so investors should expect above-average volatility around earnings, macro shocks or sector rotation.

The current share price is $153.56, with the 50-day exponential moving average at $139.81 and RSI at 67.6. The price trading well above the 50-day EMA and RSI near 67.6 shows the stock has had strong recent momentum and is approaching overbought territory on a standard 14-period basis. No debt figure is included in the current snapshot, so a complete leverage assessment would require pulling the most recent balance-sheet data directly from Agilent’s filings and conference-call commentary.

Strategic Priorities & Outlook

Agilent’s most recent 10-K filing outlines four operational priorities. The first is the segment realignment itself: the company’s three reportable units are intended to support a market-focused, customer-centric strategy. The remaining priorities are all product-level.

Agilent plans to expand the liquid chromatography application space through new columns, new services and ongoing instrument and software enhancements. It also intends to keep improving mass spectrometry portfolio capabilities, specifically performance, sensitivity, precision, robustness, ease of use and onboard intelligence. Finally, the company is pushing software and service solutions that help customers run a digitally connected smart lab, leveraging data analytics, artificial intelligence and robotics. Those priorities point to a company that is relying less on pure hardware expansion and more on an integrated workflow and recurring-revenue model.

Operational support is centralized through its order fulfillment and supply chain organization, plus a global infrastructure group that handles shared services in finance, IT, legal, procurement, workplace and HR. Manufacturing and R&D are spread across the Americas, Europe and Asia, which gives Agilent scale but also ties its cost structure and revenue recognition to cross-border operations.

Macro & Geopolitical Exposure

As a Healthcare / Medical – Diagnostics & Research company, Agilent sits at the intersection of life-sciences R&D spending, clinical diagnostics demand and global trade in precision instruments. Sector-level exposures include:

• Regulation. Diagnostic tools and research instruments face oversight from the FDA and international bodies such as the European Medicines Agency and EU In Vitro Diagnostic Medical Devices Regulation. Shifts in approval timelines, quality standards or export rules can affect product launches and margins.
• Trade and tariffs. Precision instruments, consumables and components move across borders. Tariffs on Chinese or other Asian-sourced parts could raise input costs, while retaliatory measures could constrain demand in key export markets.
• Currency risk. With manufacturing and sales spread across the U.S., Europe and Asia, exchange-rate swings can influence translated revenue and the relative competitiveness of regional production.
• R&D funding cycles. Academic, government and pharmaceutical research budgets drive demand for chromatography, mass spectrometry and related lab tools. Any slowdown in NIH, EU framework or biotech venture funding can soften instrument orders.
• Supply chain. Semiconductor, sensor and specialty-glass inputs are critical for instrument production. Supply disruptions or price spikes can affect delivery schedules and gross margin.

These themes are general to the diagnostics-and-research industry and represent background risks that investors typically monitor for instrument-heavy companies.

Recent Developments

Recent headlines have been light on fundamental news and heavy on positioning ahead of the upcoming earnings report. On August 23, 2026, defenseworld.net reported that EP Wealth Advisors LLC acquired 11,685 shares of Agilent. The prior day, August 22, 2026, defenseworld.net noted that Allworth Financial LP took a new $2.71 million position in the stock. Both are routine 13F-style disclosures, but they show that institutional money has been accumulating the name in the weeks before the next quarterly release.

On August 21, 2026, zacks.com published “Exploring Analyst Estimates for Agilent (A) Q3 Earnings, Beyond Revenue and EPS,” and 247wallst.com ran “Agilent Stock Has A Catalyst Coming On August 26 That Investors Should Not Ignore.” That catalyst is the upcoming earnings report scheduled for August 26, 2026 after the market close. The current consensus EPS estimate is $1.49.

Earnings Behavior & Post-Earnings Drift

Agilent has a strong recent earnings record. Over the last eight reported quarters, the company has beaten the market’s real expectation in six out of eight quarters, for a beat rate of 86%. The average earnings surprise across those eight quarters is 2.5%. The average five-trading-day price move after earnings is 5.1%, with the drift direction classified as up.

The most recent four quarters illustrate how sensitive the stock has been to results:

• May 27, 2026: EPS came in at $1.49 versus an estimate of $1.41, a 5.7% surprise. The stock jumped 16.87% the next session and 18.61% over the following five trading days.
• February 25, 2026: EPS was $1.36 versus $1.37, a -0.7% miss. The stock declined 3.01% the next day and 3.35% over the next five trading days.
• November 24, 2025: EPS was $1.59 versus $1.58431, a 0.4% beat. The stock rose 2.34% the next session, but gave back ground and fell 3.12% over the following five trading days.
• August 27, 2025: EPS came in at $1.37, exactly matching the $1.37 estimate for a 0% surprise. The stock still gained 5.28% the next day and 8.25% over the next five trading days.

The takeaway is that Agilent has a history of beating expectations and drifting higher over the five days after results, but the magnitude of the reaction can vary and occasionally reverses. With the next report due on August 26, 2026 after the close and the consensus EPS estimate at $1.49, traders and investors should be prepared for meaningful volatility given the 1.23 beta and the company’s tendency to move sharply around earnings.

For a deeper dive into how analysts and institutional investors are positioned around Agilent ahead of the next report, consider looking at the full institutional verdict and consensus estimate breakdown.